Developing Potent and Selective TBK1 Molecular Glue Degraders for Cancer Immunotherapy
John Caldwell, Patrick R. A. Zanon, Iona Ferguson, Stephen T. Hallett, Tencho Tenev, Natalia Serrano-Aparicio, Russell J.H. Wood, Shakil Khan, Sidonie Wicky John, Rebecca Wilson, Matthew T. Warren, P. Craig McAndrew, Martin Steger, Denise Winkler, Uli Ohmayer, , Zoran Ranković
This paper develops a first-in-class TBK1 molecular glue degrader, CCT412020, which enhances anti-tumour immunity and overcomes immune checkpoint blockade resistance.
bioRxiv · Feb 2, 2026 · PreprintCancer Biology